Nanogen Expands European Distribution Network for Point-of-Care Diagnostics

Mar 08, 2005, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of advanced diagnostic products, announced today its subsidiary SynX
 signed five new European distributors for its point-of-care products.  The
 additional distribution agreements significantly increase SynX's coverage to
 28 European nations.  All of SynX's European distributors were selected based
 on prior experience in the point-of-care medical device and equipment sector,
 as well as knowledge with cardiac and central nervous system diseases.  Each
 partner will be responsible for the distribution and marketing of SynX's
 point-of-care tests and research oriented products for congestive heart
 failure (CHF) and myocardial infarction.  Expected to be commercially
 available in 2005, the CHF diagnostic product will measure NT-proBNP
 (N-terminal pro-hormone brain natriuretic peptide), a sensitive and specific
 biomarker for the diagnosis of congestive heart failure.
     "These new distribution partners complement our existing distributor
 networks and provide us with significant relationships with point-of-care
 diagnostic decision makers in the hospital and research market segments," said
 Howard C. Birndorf, Nanogen's chairman of the board and chief executive
 officer.  "Development of our congestive heart failure test is progressing and
 expansion of our distribution network is a key objective that will be
 important to the success of the product."
     The newly expanded network provides SynX with exposure to a potential
 customer base of over 7,500 hospitals, 4,000 clinical laboratories and almost
 11,000 cardiac specialists as measured by the European Diagnostic
 Manufacturers Association, excluding the newly emerging EU nations.
     About Nanogen, Inc.
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
 and broad suite of analyte specific reagents to develop tests to detect
 infectious diseases, drug toxicity and mutations associated with cancer,
 cardiovascular and genetic diseases.  The next generation instrument system,
 the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary
 SynX offers a line of point-of-care diagnostic tests and is building expertise
 in cardiac related health conditions.  Nanogen's ten years of pioneering
 research involving nanotechnology may also have future applications in medical
 diagnostics, biowarfare and other industries.  For additional information
 please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.